Media Coverage

Back to Media Coverage

Lilly to Fund Sigilon Therapeutics’ Encapsulated Cell Research to Treat Type 1 Diabetes

In April, insulin maker Eli Lilly announced it would invest up to $473 million in Sigilon Therapeutics and the cell encapsulation technology the Cambridge, Mass., biotech company is developing was big news in the type 1 diabetes space. We’ve been following this encapsulation technology since I met with Arturo Vegas in 2015, when he was a chemistry post doc at MIT working Robert Langer and Daniel Anderson at the Koch Institute for Integrative Cancer Research.